Most cited papers from BioCardia (United States)

BioCardia (United States)

What are the most cited papers from BioCardia (United States)?

The most cited paper from BioCardia (United States) is "Intramyocardial Stem Cell Injection in Patients With Ischemic Cardiomyopathy" (Adam R. Williams, Barry H. Trachtenberg, Darcy L. DiFede Velazquez et al., 2011), with 319 citations. Next come "An Open-Label Dose Escalation Study to Evaluate the Safety of Administration of Nonviral Stromal Cell-Derived Factor-1 Plasmid to Treat Symptomatic Ischemic Heart Failure" (135) and "Rationale and design of the Transendocardial Injection of Autologous Human Cells (bone marrow or mesenchymal) in Chronic Ischemic Left Ventricular Dysfunction and Heart Failure Secondary to Myocardial Infarction (TAC-HFT) trial: A randomized, double-blind, placebo-controlled study of safety and efficacy" (135).

Published FieldAccessCitations

Showing 17 of 17 papers. Every paper is listed.

Most cited papers, sortable by citations and release date
#	Paper
1	Intramyocardial Stem Cell Injection in Patients With Ischemic Cardiomyopathy Adam R. Williams, Barry H. Trachtenberg, Darcy L. DiFede Velazquez et al. · Circulation Research Open access	18 Mar 2011	319
2	An Open-Label Dose Escalation Study to Evaluate the Safety of Administration of Nonviral Stromal Cell-Derived Factor-1 Plasmid to Treat Symptomatic Ischemic Heart Failure Marc S. Penn, Farrell O. Mendelsohn, Gary L. Schaer et al. · Circulation Research	22 Feb 2013	135
3	Rationale and design of the Transendocardial Injection of Autologous Human Cells (bone marrow or mesenchymal) in Chronic Ischemic Left Ventricular Dysfunction and Heart Failure Secondary to Myocardial Infarction (TAC-HFT) trial: A randomized, double-blind, placebo-controlled study of safety and efficacy Barry H. Trachtenberg, Darcy L. DiFede Velazquez, Adam R. Williams et al. · American Heart Journal	Mar 2011	135
4	Transendocardial autologous bone marrow in chronic myocardial infarction using a helical needle catheter: 1-year follow-up in an open-label, nonrandomized, single-center pilot study (the TABMMI study) Luís de la Fuente, Simon H. Stertzer, Julio Argentieri et al. · American Heart Journal	20 Jun 2007	58
5	The CardiAMP Heart Failure trial: A randomized controlled pivotal trial of high-dose autologous bone marrow mononuclear cells using the CardiAMP cell therapy system in patients with post–myocardial infarction heart failure: Trial rationale and study design Amish N. Raval, Thomas D. Cook, Henricus J. Duckers et al. · American Heart Journal	3 Apr 2018	28
6	Improvement of Local Cell Delivery Using Helix Transendocardial Delivery Catheter in a Porcine Heart Yoshiaki Mitsutake, Wook Bum Pyun, Didier Rouy et al. · International Heart Journal Open access	2017	28
7	Manganese‐Enhanced Magnetic Resonance Imaging Enables In Vivo Confirmation of Peri‐Infarct Restoration Following Stem Cell Therapy in a Porcine Ischemia–Reperfusion Model Rajesh Dash, Paul J. Kim, Yuka Matsuura et al. · Journal of the American Heart Association Open access	17 Jul 2015	25
8	Evaluation of the percutaneous intramyocardial injection for local myocardial treatment Mehrdad Rezaee, Alan C. Yeung, Peter A. Altman et al. · Catheterization and Cardiovascular Interventions	31 May 2001	24
9	Point of care, bone marrow mononuclear cell therapy in ischemic heart failure patients personalized for cell potency: 12-month feasibility results from CardiAMP heart failure roll-in cohort Amish N. Raval, Peter V. Johnston, Henricus J. Duckers et al. · International Journal of Cardiology Open access	20 Oct 2020	21
10	Assessment of safety, accuracy, and human CD34+ cell retention after intramyocardial injections with a helical needle catheter in a porcine model Arun Kumar, Chris A. Haralampus, Micah A. Hughes et al. · Catheterization and Cardiovascular Interventions	14 May 2012	16
11	Exploring Heart Lymphatics in Local Drug Delivery Peter A. Altman, Richard E. Sievers, Randall A. Lee · Lymphatic Research and Biology	2003	8
12	CARDIAC REMODELING AFTER INTRAMYOCARDIAL AUTOLOGOUS BONE MARROW MONONUCLEAR CELL THERAPY FOR ISCHEMIC CARDIOMYOPATHY: 2-YEAR ECHOCARDIOGRAPHY RESULTS FROM THE CARDIAMP CELL THERAPY HEART FAILURE TRIAL OPEN-LABEL ROLL-IN COHORT Peter R. Johnston, Lavanya Bellumkonda, Amish N. Raval et al. · Journal of the American College of Cardiology Open access	Mar 2023	2
13	Autologous Cell Therapy For HFrEF: Efficacy Outcomes At Two Years For The Roll-in Cohort Of A Phase III Pivotal Trial Peter R. Johnston, Debby K. Holmes-Higgin, Amish N. Raval · Journal of Cardiac Failure	Apr 2023	1
14	Women With Heart Failure In The CardiAMP Cell Therapy Trial Leslie W. Miller, Kamran I. Muhammad, Natasha Lipson Altman et al. · Journal of Cardiac Failure	Apr 2022	1
15	Re-Establishment of SDF-1 Expression Through Non-Viral Gene Therapy Improves Clinical Parameters Through 12 Months in Patients With Ischemic Class III Heart Failure Marc S. Penn, Farrell O. Mendelsohn, Gary L. Schaer et al. · Journal of Cardiac Failure	Aug 2012	1
16	Three-year follow-up in an open-label, pilot study of transendocardial autologous bone marrow in chronic myocardial infarction using a helical needle catheter Luis de la Fuente, Simon H. Stertzer, Eduardo Peñaloza et al. · Cardiovascular revascularization medicine	Oct 2009	1
17	Transendocardial autologous bone marrow in chronic myocardial infarction using a helical needle catheter Luis de la Fuente, Stertzer Sh, Eduardo Peñaloza et al. · Cardiovascular revascularization medicine	Apr 2008	0

Citations are OpenAlex's own counts, from its 2026-09-23 snapshot, so the ranking can differ from Google Scholar or Web of Science. A paper is listed for an institution when any of its authors gave it as an affiliation; retracted papers and papers whose citation count cannot be traced to citing works are left out, and a preprint and the article it became are shown once. Release dates are OpenAlex's: where a source gave only a month or a year, that is what is shown. How the lists are chosen.